Press secretariat

The European Investment Bank (EIB) Group, the European Commission and the International Finance Corporation (IFC) are partnering to support Biovac’s development of Africa’s first end to end multi-vaccine manufacturing facility, in a landmark public private financing effort designed to strengthen the continent’s health security and vaccine self-reliance.

The European Investment Bank (EIB) is lending €20 million to Swedish biotechnology company BioLamina to expand its development of laminin technologies enabling next-generation cell therapies and more advanced, animal-free methods for drug safety testing. Cell therapies can be used to target conditions such as type 1 diabetes, Parkinson’s disease, heart failure, acute liver failure and cancer. Many of these conditions remain difficult to treat or have no cure.

The European Investment Bank (EIB) today joined Water Forward, a new global coalition bringing together multilateral development banks, governments, private investors and philanthropic partners to tackle the accelerating global water crisis.